Welcome to GenPrice! Check out our latest updates.

Shopping Cart (0)

Your cart is empty

Add some products to get started!

Etomoxir (sodium salt)

Product Specifications

UNSPSC Description

Etomoxir((R)-(+)-Etomoxir) sodium salt is an irreversible inhibitor of carnitine palmitoyltransferase 1a (CPT-1a), inhibits fatty acid oxidation (FAO) through CPT-1a and inhibits palmitate β-oxidation in human, rat and guinea pig[1].

Target Antigen

Apoptosis

Type

Reference compound

Related Pathways

Apoptosis

Applications

Cancer-programmed cell death

Field of Research

Metabolic Disease; Cancer

Assay Protocol

https://www.medchemexpress.com/_R_-__addition__-Etomoxir-sodium-salt.html

Purity

99.73

Solubility

DMSO : 50 mg/mL (ultrasonic)|H2O : 5 mg/mL (ultrasonic)

Smiles

ClC1=CC=C(OCCCCCC[C@@]2(CO2)C(O[Na])=O)C=C1

Molecular Weight

320.74

References & Citations

[1]Roddy S O'Connor, et al. The CPT1a inhibitor, etomoxir induces severe oxidative stress at commonly used concentrations.Sci Rep. 2018 Apr 19;8(1):6289.|[2]Fred Y Xu,et al.Etomoxir mediates differential metabolic channeling of fatty acid and glycerol precursors into cardiolipin in H9c2 cells.J Lipid Res. 2003 Feb;44(2):415-23.|[3]Jun Li, et al. FFA-ROS-P53-mediated mitochondrial apoptosis contributes to reduction of osteoblastogenesis and bone mass in type 2 diabetes mellitus.Sci Rep. 2015 Jul 31;5:12724.|[4]Joost J F P Luiken, et al. Etomoxir-induced partial carnitine palmitoyltransferase-I (CPT-I) inhibition in vivo does not alter cardiac long-chain fatty acid uptake and oxidation rates.Biochem J. 2009 Apr 15;419(2):447-55.Antimicrob Agents Chemother. 2018 Apr 26;62(5). pii: e01659-17. |Cancer Lett. 2024 Jun 18:217068.|Cell Death Dis. 2022 Mar 11;13(3):229.|Cell Metab. 2022 Sep 7;S1550-4131(22)00359-X.|Cell Rep. 2019 Apr 2;27(1):226-237.e4.|J Invest Dermatol. 2023 Mar 30;S0022-202X(23)01952-8.|Life Sci. 2024 Aug 1:350:122763.|Lipids Health Dis. 2024 Feb 3;23(1):37.|Mol Cell. 2020 Oct 1;80(1):43-58.e7.|Mol Cell. 2022 Jun 15;S1097-2765(22)00539-1.|Redox Biol. 2018 Jul;17:180-191.|Research Square Preprint. 2023 Aug 1.|Acta Biomater. 2022 Jul 30;S1742-7061(22)00453-6.|Acta Pharm Sin B. 2024 Nov 7.|Aging Cell. 2024 Apr 30:e14184.|Autophagy. 2024 Aug 15.|Biochem Biophys Res Commun. 2017 Feb 5;483(2):860-866.|Biochem Biophys Res Commun. 8 October 2021.|Biochim Biophys Acta Mol Basis Dis. 2024 Jun 25:167314.|bioRxiv. 2021 Mar 8.|bioRxiv. 2023 Apr 17.|bioRxiv. 2023 Nov 17.|Brain. 2024 Aug 28:awae270.|Cancer Cell Int. 2023 May 9;23(1):87.|Cancer Res. 2023 Jun 5;CAN-23-1006.|Cell Biol Int. 2024 Jun 23.|Cell Death Dis. 2023 Feb 15;14(2):125.|Cell Death Dis. 2023 Oct 6;14(10):653.|Cell Death Discov. 2024 May 1;10(1):207.|Cell Metab. 2023 Nov 16:S1550-4131(23)00386-8.|Cell Metab. 2024 May 7;36(5):969-983.e10.|Cell Physiol Biochem. 2018;48(6):2318-2336. |Cell Prolif. 2021 Sep 25;e13134.|Cell Rep Med. 2024 May 29:101592.|Cell Rep. 2021 Sep 7;36(10):109659.|Cell Rep. 2024 Feb 27;43(2):113739.|Clin Mol Hepatol. 2024 May 10.|Clin Transl Med. 2022 Sep;12(9):e1061.|Commun Biol. 2022 Dec 7;5(1):1340.|Engineering. 2024 Sep 6.|Fish Shellfish Immunol. 2024 Aug 12:109829.|Food Chem Toxicol. 2022 Oct 5;113450.|Free Radic Biol Med. 2019 Sep;141:372-382.|Free Radic Biol Med. 2022 Aug 8;190:94-104.|Front Biosci (Landmark Ed). 2024 Feb 6;29(2):66.|Front Immunol. 2022 Mar 10;13:771732.|Front Oncol. 2021 Apr 22;11:665763.|Front Oncol. 2021 Apr 6.|Front Pharmacol. 2022 May 16;13:848957.|Hepatology. 2022 Jan 14.|Infect Genet Evol. 2020 Nov;85:104552.|Int J Biol Sci. 2021 Oct 11;17(15):4207-4222.|Int J Biol Sci. 2022 Mar 14;18(6):2484-2496.|J Agric Food Chem. 2024 May 29.|J Biol Chem. 2024 Jul 11:107549.|J Biomed Mater Res A. 2022 Aug;110(8):1448-1459.|J Cell Biol. 2022 Dec 5;221(12):e202207022.|J Cell Sci. 2022 Jul 1;jcs.259090.|J Invest Dermatol. 2023 Mar 30;S0022-202X(23)01952-8.|J Orthop Surg Res. 2023 May 26;18(1):386.|Mol Cell. 2024 Jun 21:S1097-2765(24)00477-5.|Mol Metab. 2024 May 4:101953.|Nat Commun. 2021 Jun 16;12(1):3660.|Nat Commun. 2022 Jun 17;13(1):3486.|Nat Commun. 2024 Aug 3;15(1):6587.|Nat Commun. 2024 May 7;15(1):3805.|Oncol Rep. 2023 Jul;50(1):141.|Oncol Rep. 2023 May 29.|Oncotarget. 2016 Oct 11;7(41):67071-67086.|Pharmacol Res. 2021 Jul 31;105796.|Proc Natl Acad Sci U S A. 2021 Nov 16;118(46):e2105950118.|Redox Biol. 2018 Oct;19:412-428. |Redox Biol. 2021 Jul 26;46:102082.|Research Square Preprint. 2020 Sep.|Research Square Preprint. 2022 Feb.|Rheumatology (Oxford). 2024 Jun 5:keae320.|Sci Adv. 2023 Apr 14;9(15):eadf8522.|Sci Immunol. 2023 Sep 29;8(87):eabq2424.|Sci Rep. 2024 Jan 18;14(1):1600.|Science Partner Journals. 2023 Feb 14.|SSRN. 6 Dec 2022.|Stem Cell Res Ther. 2024 Sep 27;15(1):328.|Theranostics. 2020 May 16;10(14):6483-6499. |Universidade de São Paulo. Ribeirão Preto, 2021.|Vet Microbiol. 2023 Nov 30:288:109932.

Shipping Conditions

Blue Ice

Storage Conditions

-20°C (Powder, protect from light, stored under nitrogen)

Product Datasheet

http://file.medchemexpress.com/batch_PDF/HY-50202A/Etomoxir-sodium-salt-DataSheet-MedChemExpress.pdf

Product MSDS

http://file.medchemexpress.com/batch_PDF/HY-50202A/Etomoxir-sodium-salt-SDS-MedChemExpress.pdf

Clinical Information

No Development Reported

CAS Number

828934-41-4

Available Sizes

Curated Selection

Explore Other Products

Discover premium biology products from our extensive collection of 20M+ items

Cy3-Linked Polyclonal Antibody to Oncomodulin (OCM)
MBS2079869-01 0.1 mL

Cy3-Linked Polyclonal Antibody to Oncomodulin (OCM)

Ask
View Details
Cy3-Linked Polyclonal Antibody to Oncomodulin (OCM)
MBS2079869-02 0.2 mL

Cy3-Linked Polyclonal Antibody to Oncomodulin (OCM)

Ask
View Details
Cy3-Linked Polyclonal Antibody to Oncomodulin (OCM)
MBS2079869-03 0.5 mL

Cy3-Linked Polyclonal Antibody to Oncomodulin (OCM)

Ask
View Details
Cy3-Linked Polyclonal Antibody to Oncomodulin (OCM)
MBS2079869-04 1 mL

Cy3-Linked Polyclonal Antibody to Oncomodulin (OCM)

Ask
View Details
Cy3-Linked Polyclonal Antibody to Oncomodulin (OCM)
MBS2079869-05 5 mL

Cy3-Linked Polyclonal Antibody to Oncomodulin (OCM)

Ask
View Details
Cy3-Linked Polyclonal Antibody to Oncomodulin (OCM)
MBS2079869-06 5x 5 mL

Cy3-Linked Polyclonal Antibody to Oncomodulin (OCM)

Ask
View Details